RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Cannaccord 42nd
In vivo they showed plasm concentrations of released docetaxel was low suggesting most of docetaxel was remained with the peptide now in the presentation clinically they claimed the below.
“Notably, the levels of free docetaxel are low, at only 11% of those observed at docetaxel treatment dosage of 75 mg/m2.”
Today Paul also mentioned the free docetaxel is low or something in those lines so as we know the MTD for docetaxel is 100mg/m2 if I recall correctly equivalent to TH1902 230mg/m2 to put in the concept having only 11% free docetaxel among patients treated at 75mg/m2 (docetaxel alone)for patients treated with 300/420 mg/m2 of the PDC the plasma concentration of docetaxel is rather low plasma. I believe the FDA would be closely looking at those numbers going forward as low free concentration of the docetaxel means the PDC is stable during the half life of the drug and docetaxel has been internalized into cancer cells at 300mg/m2, less of target delivery absent adverse effects, affinity to the receptor, internalized etc. and any potential efficacy would be due to internalization and not the plasma concentration of the docetaxel.
Interpret the way you like but it is the reasoning behind the targeted drug delivery.